Thousand Oaks biotech firm closes $140M funding round
Capsida Biotherapeutics, a biotechnology startup based in Thousand Oaks, announced April 29 that it is emerging from “stealth mode” with a $140 million funding round led by Westlake Village BioPartners and Versant Ventures. The Series A round includes $50 million from Westlake Village BioPartners, a venture capital firm in Thousand Oaks focused on biotech startups Read More →
Amgen to buy cancer treatment biotech firm for $1.9B
Thousand Oaks-based Amgen, one of the biggest biotech companies in the world, will get bigger with the $1.9 billion acquisition of Five Prime Therapeutics, a clinical-stage biotech company developing stomach cancer therapies. Amgen announced the acquisition March 4 and the deal is expected to close by the end of the second quarter of 2021. Under Read More →
MannKind stock dips on report of 2020 losses, but company touts fourth quarter comeback
MannKind Corp. struggled during 2020, but impressive financial results from its final quarter could be a sign of good things to come for the Westlake Village biotech company. MannKind, which develops drugs and treatments for those suffering from diabetes and pulmonary arterial hypertension, reported a net loss of $57.2 million in fiscal year 2020, up Read More →
‘Golden age of biotechnology’ comes to Conejo Valley
Westlake Village BioPartners has launched two new funds worth a total of $500 million, bringing the total raised by the firm to more than $820 million since it was founded in 2018.
MannKind makes $12.5M pharma buy
MannKind Corp., a biotech company based in Westlake Village, announced Dec. 7 that it has acquired a QrumPharma, a privately held biotech company, in a $12.5 million deal. MannKind has purchased all outstanding capital stock of QrumPharma for $3.5 million in cash and just over 3 million shares of MannKind common stock. At MannKind’s stock Read More →
Tri-county stocks reverse prior day’s losses, gain 9.3 percent
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Arcutis planning $152 million IPO
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
